Literature DB >> 29053671

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein.

Shubhendu Sen Roy1, Huy Cong Xuan Nguyen1, Thomas A Angelovich2, Anna C Hearps3, Diana Huynh4, Anthony Jaworowski5, Theodoros Kelesidis6.   

Abstract

Low high-density lipoprotein cholesterol (HDL-C) levels are one of the most powerful independent negative predictors of atherosclerotic cardiovascular disease (CVD). The structure and function of HDL rather than HDL-C may more accurately predict atherosclerosis. Several HDL protein and lipid compositional changes that impair HDL function occur in inflammatory states such as atherosclerosis. HDL function is usually determined by cell based assays such as cholesterol efflux assay but these assays have numerous drawbacks lack of standardization. Cell-free assays may give more robust measures of HDL function compared to cell-based assays. HDL oxidation impairs HDL function. HDL has a major role in lipid peroxide transport and high amount of lipid peroxides is related to abnormal HDL function. Lipid-probe interactions should be considered when interpreting the results of non-enzymatic fluorescence assays for measuring the lipid oxidative state. This motivated us to develop a cell-free biochemical enzymatic method to assess HDL lipid peroxide content (HDLox) that contributes to HDL dysfunction. This method is based on the enzyme horseradish peroxidase (HRP) and the fluorochrome Amplex Red that can quantify (without cholesterol oxidase) the lipid peroxide content per mg of HDL-C. Here a protocol is describedfor determination of HDL-lipid peroxidation using the fluorochrome reagent. Assay variability can be reduced by strict standardization of experimental conditions. Higher HDLox values are associated with reduced HDL antioxidant function. The readout of this assay is associated with readouts of validated cell-based assays, surrogate measures of cardiovascular disease, systemic inflammation, immune dysfunction, and associated cardiovascular and metabolic risk phenotypes. This technical approach is a robust method to assess HDL function in human disease where systemic inflammation, oxidative stress and oxidized lipids have a key role (such as atherosclerosis).

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29053671      PMCID: PMC5752402          DOI: 10.3791/56325

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  58 in total

1.  L-4F differentially alters plasma levels of oxidized fatty acids resulting in more anti-inflammatory HDL in mice.

Authors:  Satoshi Imaizumi; Victor Grijalva; Mohamad Navab; Brian J Van Lenten; Alan C Wagner; G M Anantharamiah; Alan M Fogelman; Srinivasa T Reddy
Journal:  Drug Metab Lett       Date:  2010-08

Review 2.  The antioxidant properties of serum albumin.

Authors:  Marjolaine Roche; Philippe Rondeau; Nihar Ranjan Singh; Evelyne Tarnus; Emmanuel Bourdon
Journal:  FEBS Lett       Date:  2008-05-12       Impact factor: 4.124

Review 3.  High-density lipoprotein--the clinical implications of recent studies.

Authors:  D J Gordon; B M Rifkind
Journal:  N Engl J Med       Date:  1989-11-09       Impact factor: 91.245

4.  Application of the Amplex red/horseradish peroxidase assay to measure hydrogen peroxide generation by recombinant microsomal enzymes.

Authors:  Vladimir Mishin; Joshua P Gray; Diane E Heck; Debra L Laskin; Jeffrey D Laskin
Journal:  Free Radic Biol Med       Date:  2010-02-25       Impact factor: 7.376

5.  Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures.

Authors:  B J Van Lenten; S Y Hama; F C de Beer; D M Stafforini; T M McIntyre; S M Prescott; B N La Du; A M Fogelman; M Navab
Journal:  J Clin Invest       Date:  1995-12       Impact factor: 14.808

Review 6.  The role of dysfunctional HDL in atherosclerosis.

Authors:  Mohamad Navab; Srinivasa T Reddy; Brian J Van Lenten; G M Anantharamaiah; Alan M Fogelman
Journal:  J Lipid Res       Date:  2008-10-27       Impact factor: 5.922

7.  HDL lipid composition is profoundly altered in patients with type 2 diabetes and atherosclerotic vascular disease.

Authors:  C Morgantini; D Meriwether; S Baldi; E Venturi; S Pinnola; A C Wagner; A M Fogelman; E Ferrannini; A Natali; S T Reddy
Journal:  Nutr Metab Cardiovasc Dis       Date:  2014-01-22       Impact factor: 4.222

8.  Modification of high density lipoprotein by myeloperoxidase generates a pro-inflammatory particle.

Authors:  Arundhati Undurti; Ying Huang; Joseph A Lupica; Jonathan D Smith; Joseph A DiDonato; Stanley L Hazen
Journal:  J Biol Chem       Date:  2009-09-02       Impact factor: 5.157

9.  Anti-inflammatory and antioxidant properties of HDLs are impaired in type 2 diabetes.

Authors:  Cecilia Morgantini; Andrea Natali; Beatrice Boldrini; Satoshi Imaizumi; Mohamad Navab; Alan M Fogelman; Ele Ferrannini; Srinivasa T Reddy
Journal:  Diabetes       Date:  2011-08-18       Impact factor: 9.461

10.  HDL redox activity is increased in HIV-infected men in association with macrophage activation and non-calcified coronary atherosclerotic plaque.

Authors:  Markella V Zanni; Theodoros Kelesidis; Michael L Fitzgerald; Janet Lo; Suhny Abbara; Bryan Wai; Eleni Marmarelis; Nicholas J Hernandez; Otto O Yang; Judith S Currier; Steven K Grinspoon
Journal:  Antivir Ther       Date:  2014-02-17       Impact factor: 1.679

View more
  4 in total

1.  The impact of aerobic and isometric exercise on different measures of dysfunctional high-density lipoprotein in patients with hypertension.

Authors:  Nikolaos Pagonas; Stergios Vlatsas; Frederic Bauer; Felix S Seibert; B Sasko; I Buschmann; O Ritter; Theodoros Kelesidis; Timm H Westhoff
Journal:  Eur J Prev Cardiol       Date:  2019-05-08       Impact factor: 7.804

2.  Human T lymphotropic virus type 1 and risk of cardiovascular disease: High-density lipoprotein dysfunction versus serum HDL-C concentrations.

Authors:  Sara Samadi; Samaneh Abolbashari; Zahra Meshkat; Amir Hooshang Mohammadpour; Theodoros Kelesidis; Aida Gholoobi; Mehrane Mehramiz; Mahla Tabadkani; Fatemeh Sadabadi; Razieh Dalirfardouei; Gordon A Ferns; Majid Ghayour-Mobarhan; Amir Avan
Journal:  Biofactors       Date:  2019-01-29       Impact factor: 6.113

3.  High-density lipoprotein lipid peroxidation as a molecular signature of the risk for developing cardiovascular disease: Results from MASHAD cohort.

Authors:  Sara Samadi; Mehrane Mehramiz; Theodoros Kelesidis; Majid Ghayour Mobarhan; Amir Hosein Sahebkar; Habibollah Esmaily; Mohsen Moohebati; Zahra Farjami; Gordon A Ferns; Amir Hooshang Mohammadpour; Amir Avan
Journal:  J Cell Physiol       Date:  2019-02-19       Impact factor: 6.384

4.  Race and sex differences in HDL peroxide content among American adults with and without type 2 diabetes.

Authors:  Shelby M Flaherty; Elizabeth K Wood; Carol D Ryff; Gayle D Love; Theodoros Kelesidis; Loni Berkowitz; Guadalupe Echeverría; Katherine Rivera; Attilio Rigotti; Christopher L Coe
Journal:  Lipids Health Dis       Date:  2022-02-06       Impact factor: 3.876

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.